VNVC Vaccin and Biological Factory has just signed a cooperation agreement to transfer comprehensive technology for the production of high-tech, advanced biological drugs to help treat acute, chronic and dangerous infectious diseases with Medsintez Pharmaceutical Company (Russian Federation). The signing ceremony took place on September 12 in Hanoi, witnessed by Russian Minister of Health Mikhail Murashko and Party Central Committee member and Minister of Health of Vietnam Dao Hong Lan.
Realizing extensive cooperation between Vietnam and Russia
Previously, in May 2025 in Moscow, under the witness of Russian President Putin and General Secretary To Lam, the two countries' health ministers signed a cooperation agreement and witnessed VNVC signing a comprehensive cooperation agreement with the Russian Direct Investment Fund (RDIF) - the highest representative of Russian pharmaceutical research and production agencies as well as other health agencies.
This cooperation between VNVC and Medsintez is a step to realize extensive cooperation between the two countries to soon bring Vietnam to access and produce the world's leading advanced biological drugs from Russia in the treatment of diabetes, obesity, vascular diseases, viral diseases, especially the treatment of dengue fever.
Immediately after the signing, Medsintez and VNVC will carry out the steps of transferring Medsintez's advanced biological drug production technology at the VNVC Vaccine and Food Factory, cooperate in researching, developing and clinically researching new drugs and vaccines, and distributing Medsintez's high-quality pharmaceutical products in Vietnam and ASEAN countries.
It is expected that in the coming time, many advanced biological drug categories of Medsintez will be transferred to production at the VNVC Vaccine and Biological Factory, such as recombined albumin and insulin, disposable and reusable insulin pen, diabetes medication (liraglutide, semaglutide), anticoagulants Heparin to help prevent and treat thrombosis complications that cause blood clots leading to strokes, heart attack, antiseptic drug Triazavirin, follicular stimulation hormone for infertility treatment...
In particular, the two sides will discuss the coordination of clinical research on the antiseptic drug Triazavirin in the treatment of dengue fever, a disease that causes hundreds of thousands of cases and dozens of deaths each year in Vietnam but has no specific treatment, contributing to improving the effectiveness of disease prevention and control. This is a drug recommended by the Russian Ministry of Health for the treatment of influenza and COVID-19, and is assessed to have the potential to expand the prevention of viral diseases.
Shortening the roadmap to master high technology in drug and vaccine production
Speaking at the event, Russian Minister of Health Mikhail Murashko said that Russia has provided many treatment technologies from oncology, organ transplantation to developing a modern health system for the world. During the COVID-19 pandemic, Russia has provided medicine, experts and Sputnik vaccine to nearly 70 countries.
The cooperation event between Vietnam and Russia will bring common benefits, aiming at the highest goal of protecting people's health and improving the quality of the health sector of the two countries, said Mr. Mikhail Murashko.
Ms. Dao Hong Lan - Minister of Health - on behalf of the Ministry and people of Vietnam thanked the support of the Russian Government and the Ministry of Health over the past decades for supporting Vietnam in training doctors, providing medicine, vaccines, modern techniques and building medical facilities. She believes that cooperation between research institutes, high-tech medical centers and prestigious units in the medical field of the two countries will open up opportunities for research, technology transfer, vaccine and treatment production, contributing to improving people's health and strengthening the friendship between the two countries.
Previously, the VNVC Vaccine and Biological Factory officially started construction in May 2025, in Tay Ninh province, with a total initial investment of more than VND 2,000 billion. This is a strategic project, oriented to become one of the most modern vaccine and biological product manufacturing facilities in the region, applying the international GMP standards of WHO, EU ( Europe), FDA (USA).
Mr. Ngo Chi Dung - Chairman of the Board of Directors and General Director of VNVC Vaccin and Food Factory - said that cooperation with Medtezsin is one of many in-depth cooperation that VNVC as well as members of the ecosystem, the Tam Anh Clinical Medicine and Pharmacy System, will sign with research institutes, hospitals and major Russian pharmaceutical companies.
Along with Government agencies and health units, the Tam Anh - VNVC health ecosystem is making efforts to realize the contents of Resolutions 57, 28, 68, and 72 of the Politburo on breakthroughs in people's health care, improving autonomy in the production of pharmaceuticals and high-tech vaccines, serving Vietnamese people and international tourists for medical examination and treatment in Vietnam, contributing to ensuring national health security.
It is expected that by the end of 2027, VNVC Vaccin and Food Factory will start producing new-generation vaccines and advanced biological drugs from many countries around the world right in Vietnam, said Mr. Ngo Chi Dung.
The event of VNVC signing with Medsintez is not only an important step forward for VNVC in the process of international cooperation and integration, but also affirms the ability of Vietnamese enterprises to receive and master the world's leading advanced technologies. This cooperation also opens up opportunities for Vietnam to soon access high-quality biological drugs in the treatment of infectious diseases and dangerous chronic diseases, gradually shortening the technology mastery roadmap, reducing import costs, moving towards domestic supply autonomy and towards export, thereby affirming its position as a prestigious vaccine production and supply center - biological products in the ASEAN region.
Before Medsintez, VNVC also signed cooperation agreements with partners with leading capabilities in the fields of biotechnology such as Sanofi (France), Pfizer (USA), the National Center for Epidemiology and microbiology of Gamaleya, and the Russian Binnopharm Pharmaceutical Group to promote research, investment, technology transfer and trade of biotechnology drugs and high-tech vaccines including mRNA vaccines for cancer treatment for production at a factory in Vietnam.
